AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 304 min read$INV

Innventure, Inc. (INV): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Innventure, Inc. (INV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. innv-20260626 0002001557 False 0002001557 2026-04-14 2026-04-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie

Original reporting
SEC EDGAR 8-K
Published Jun 30, 2026, 12:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$INV
Neutral
medium confidence
Mentioned
$INV
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INVNeutralMed
01

Why it matters

The disclosure provides concrete governance and compensation mechanics (consulting agreement for the outgoing CEO; salary/bonus and $1.0M RSU grant for the incoming CEO), which can drive near-term sentiment and positioning ahead of the Oct. 1, 2026 effective date.

02

Market read

This is a primary-source leadership transition with specified compensation and equity vesting terms, offering a tradable catalyst for positioning and volatility management.

03

What to watch

Equity vesting through the consulting term and the size/structure of the new CEO’s RSU grant could matter for insider/compensation optics and future dilution expectations, even without immediate operational metrics.

Relevance 6/10Novelty 6/10Timing: effective Oct. 1, 2026 CEO transition disclosed in a June 30, 2026 8-K

Background

Innventure filed an SEC Form 8-K (Item 5.02) announcing a planned CEO retirement and a new CEO appointment, alongside consulting/employment compensation details.

Company-level read

Ticker impact

$INVNeutralMedium confidence
Context

Innventure discloses CEO Gregory W. Haskell’s planned retirement on Oct. 1, 2026 and appoints Dr. William Grieco as CEO effective the same date.

Expected impact

Short-term: modest volatility around transition expectations; medium-term: depends on execution of plastic-waste commercialization strategy under new CEO.

Evidence & confidence

The filing is a primary-source 8-K detailing a scheduled CEO change and new CEO employment terms, but it provides no financial guidance, deal, or operational KPI changes.

Market effects

Sector

May modestly affect investor perception of management quality in cleantech/plastics-to-chemicals commercialization narratives, but no sector-wide policy or regulatory change is cited.

Regional

No specific regional macro linkage; impact is company-specific within Nasdaq small/mid-cap sentiment.

Global

No direct global demand/supply or international regulatory catalyst mentioned; relevance is limited to company leadership and subsidiary commercialization execution.

Counterpoint

What could challenge this read

Because the CEO change is scheduled months ahead and framed as non-disagreement, the market may already be pricing it; stock reaction could be muted versus typical leadership-change headlines.

Key entities

  • public_company
    Innventure, Inc.

    Nasdaq-listed company (INV) reporting the CEO transition and related compensatory arrangements via Form 8-K.

  • person
    Gregory W. Haskell

    Outgoing CEO and Class I director retiring effective Oct. 1, 2026; enters a consulting agreement through July 15, 2027.

  • person
    Dr. William Grieco

    Incoming CEO and Class I director effective Oct. 1, 2026; founding CEO of Refinity and former CTO of Innventure.

  • subsidiary
    Refinity Holdings, LLC

    Operating company subsidiary focused on commercializing technology converting plastic waste into chemical intermediaries; central to Grieco’s background.

Read at source← All news

Related articles

AUG 13
$INVMed

Innventure, Inc. (INV): Results of Operations and Financial Condition

Innventure, Inc. (INV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a991innventure-2q26earning.htm EX-99.1 Document Exhibit 99.1 Innventure Reports Second Quarter 2026 Results Accelsius focused on execution against foundational milestones to strengthen path to scaled two-phase adoption ORLANDO, Fla., August 13, 2026 (GLOBAL NEWSWIRE) –

SEC EDGAR 8-K4 min
JUN 4
$INVMed

Placing and Offer for Subscription

The Board of The Investment Company plc (LSE: INV) published a circular to shareholders on 4 June 2026 outlining proposals for the company’s future. Plans include appointing Dowgate Wealth Limited as portfolio manager, adopting a new scarcity/resilience-focused investment policy, raising funds via a placing and offer for subscription, and providing a 100% exit option for qualifying shareholders not wishing to stay. Proposals require shareholder approval.

investegate.co.uk6 min
MAY 27
$INVMedAI 9/10

Innventure (INV) Q4 2025 Earnings Transcript

Innventure (INV) reported 2025 revenue of $2.1m vs. $1.2m in 2024, driven by Accelsius and AeroFlexx. Accelsius delivered $1.6m revenue (vs. $0.3m) and secured $50m+ in new Q1 bookings; Accelsius Series B closed at a ~$665m post-money valuation. Management expects Accelsius to be cash-flow positive by year-end. Cash rose to $65.4m; adjusted EBITDA loss was $78.8m.

fool.com6 min
AUG 13
$MPLTMedAI 8/10

MapLight Raises $150 M PIPE To Fund CNS Pipeline

MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.

rttnews.com2 min
AUG 13
$TSNMedAI 8/10

Tyson Foods will close or sell three US beef facilities as industry struggles

Tyson Foods said it will close or sell three US beef facilities, ending operations at Joslin, Illinois and Eagle Mountain, Utah, and pursuing the sale of Pasco, Washington, while shifting capacity to other sites. The move follows prior Tyson beef shutdowns and comes as a 75-year cattle supply trough drives losses. Tyson forecast a $500m to $650m adjusted beef operating loss for fiscal 2026.

investing.com6 min
AUG 13
$MVISMedAI 8/10

MicroVision, Inc.: MicroVision Announces Launch of Proposed Public Offering

MicroVision (NASDAQ:MVIS) said it has commenced a proposed public offering of units, each unit consisting of one share of common stock (or a pre-funded warrant in lieu) and one warrant to buy one share. MicroVision will sell the shares and warrants, with final terms to be set at pricing. Net proceeds are for general corporate purposes, including working capital and capex.

finanznachrichten.de2 min